BioPharmSignal logoBioPharmSignal

Biotech News

Telix Reports Third Quarter 2026 Financial Performance

Telix Pharmaceuticals Ltd (TLX)Telix Pharmaceuticals LtdEarnings

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).

Related news

TLXTelix Pharmaceuticals Ltd2026-10-19 05:30 EST

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

TLXTelix Pharmaceuticals Ltd2026-09-09 10:30 EST

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

View all latest news

Telix Pharmaceuticals Ltd

Recent company news

TLXTelix Pharmaceuticals Ltd2026-10-20 22:10 EST

Telix Reports Third Quarter 2026 Financial Performance

TLXTelix Pharmaceuticals Ltd2026-10-19 05:30 EST

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

TLXTelix Pharmaceuticals Ltd2026-10-06 10:30 EST

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

TLXTelix Pharmaceuticals Ltd2026-09-21 00:55 EST

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

TLXTelix Pharmaceuticals Ltd2026-09-14 10:30 EST

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

Stock data

Close
9.54 USD
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States